Captrust Financial Advisors acquired a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 80 shares of the biopharmaceutical company’s stock, valued at approximately $30,000.

A number of other hedge funds also recently added to or reduced their stakes in REGN. Capital World Investors grew its holdings in Regeneron Pharmaceuticals by 5.3% during the 3rd quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock worth $2,579,522,000 after acquiring an additional 322,051 shares during the last quarter. BlackRock Inc. grew its holdings in Regeneron Pharmaceuticals by 1.1% during the 4th quarter. BlackRock Inc. now owns 5,929,225 shares of the biopharmaceutical company’s stock worth $2,214,564,000 after acquiring an additional 67,241 shares during the last quarter. Vanguard Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares during the last quarter. Vanguard Group Inc grew its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares during the last quarter. Finally, FMR LLC grew its holdings in Regeneron Pharmaceuticals by 17.0% during the 3rd quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after acquiring an additional 728,104 shares during the last quarter. Institutional investors and hedge funds own 66.79% of the company’s stock.

NASDAQ:REGN opened at $405.50 on Thursday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. Regeneron Pharmaceuticals Inc has a 52 week low of $281.89 and a 52 week high of $442.00. The firm has a market capitalization of $44.29 billion, a PE ratio of 20.48, a PEG ratio of 1.64 and a beta of 1.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, beating the Zacks’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. During the same period in the prior year, the firm posted $5.23 EPS. The company’s quarterly revenue was up 21.9% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current year.

In other news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Joseph L. Goldstein sold 1,791 shares of the company’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $5,786,740. The disclosure for this sale can be found here. Corporate insiders own 12.42% of the company’s stock.

A number of equities research analysts have weighed in on the stock. BidaskClub raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Cantor Fitzgerald reissued a “hold” rating and set a $441.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. ValuEngine raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 15th. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 5th. Finally, BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals to $412.00 and gave the stock a “market perform” rating in a report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $413.76.

COPYRIGHT VIOLATION WARNING: “Captrust Financial Advisors Takes $30,000 Position in Regeneron Pharmaceuticals Inc (REGN)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2019/03/21/captrust-financial-advisors-takes-30000-position-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Put Option Volume

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.